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Abstract 
 
Kounis syndrome (KS) is a hypersensitivity coronary disorder induced by various allergens. It is 
a rare condition which has been reported in every age group (2-90 years) and in every race and 
geographic location. Its incidence has been reported to range from 7.9 to 19.4 per 100,000. The 
presentation of the detrimental effects of KS on coronary arteries ranges from vasospastic angina 
to allergic myocardial infarction.  
Drugs are the major iatrogenic cause of KS, but virtually everything in the environment around 
us can cause KS. In recent years contrast mediums used in the radiologic investigation have 
come forth as a leading cause of anaphylaxis.  Gadolinium is a rare earth metal that is used in 
contrast mediums for magnetic resonance imaging and is generally considered to be safe.  
This is a case of 52-year-old female who developed KS after receiving gadobenate dimeglumine, 
a gadolinium based contrast medium (GBCM) for MRI of the brain as a work up for metastatic 
renal cell carcinoma. Her EKG was remarkable for ST elevations in the inferior leads. Cardiac 
catheterization was preformed which did not reveal any significant obstructive coronary artery 
disease. Patient was treated with anti-histamines, corticosteroids and norepinephrine after which 
she recovered and discharged home stable.  GBCM induced KS is very rare and to our 
knowledge this is the third case of Kounis syndrome reported in association with gadobenate 
dimeglumine. 
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Introduction 
 
Coronary vasospasm is referred to as constriction of coronary arteries that causes complete 
occlusion or near to complete occlusion of an artery leading to decreased blood flow to the 
myocardium.1 Anaphylaxis is an immediate allergic reaction that has the propensity to cause 
severe coronary vasospasms.2,3 Anaphylaxis virtually affects all major systems of the body 
including the cardiovascular system making the heart a target organ.4  
 
Kounis syndrome is a hypersensitivity coronary disorder induced by various allergens.5 It is a 
rare condition which has been reported in every age group (2-90 years) and in every race and 
geographic location. Its incidence has been reported to range from 7.9 to 19.4 per 100,000.5 In 
response to an allergen, inflammatory cells secrete mediators such a histamine and tryptase 
causing changes to the systemic and coronary vasculature. The presentation of the detrimental 
effects of KS on coronary arteries ranges from vasospastic angina to allergic myocardial 
infarction.5  
 
Drugs are the major iatrogenic cause of KS, but virtually everything in the environment around 
us can cause KS. In recent years contrast mediums used in the radiologic investigation have 
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come forth as a leading cause of anaphylaxis.6,7 Gadolinium is a rare earth metal that is used in 
contrast mediums for magnetic resonance imaging and is generally considered to be safe.8 Here 
we report a very rare case of KS in response to gadobenate dimeglumine (a gadolinium based 
contrast medium), which is to our knowledge the third case of Kounis syndrome reported in 
association with gadobenate dimeglumine.  
 
Case Presentation 
 
A 52-year-old female with no known allergies has past medical history of a unilateral 
nephrectomy due to renal cell carcinoma years ago and chronic kidney disease (CKD). She was 
recently diagnosed with locally advanced and recurrent renal cell carcinoma with metastatic 
lesion to the left lower lung and presented to the radiology department for an MRI brain with 
contrast.  In the MRI suite, the patient was given gadolinium contrast after which she developed 
severe sub-sternal chest pain and shortness of breath that was associated with nausea and 
vomiting.  Shortly after that she collapsed with systolic blood pressure in the 80s so patient was 
intubated and given IV fluid boluses. ECG was done immediately and that showed ST elevations 
in inferior leads (Figure 1) and code heart was called. Right-sided ECG was done which showed 
right ventricular infarct with ST elevation in V3R-V6R (Figure 2). Troponins were checked by 
emergency department physician and trended with a peak of 1.12. The patient was emergently 
transferred to the cath lab where a left heart catheterization was performed which demonstrated 
that the patient had non-obstructive coronary artery disease with 20% RCA stenosis (Figure 3 & 
Figure 4); a pulmonary angiogram was also done which ruled out pulmonary embolism (Figure 
5).  While patient was still on the table of the cath lab, repeat ECG was performed and showed 
normal sinus rhythm with the resolution of ST-segment elevations (Figure 6).  
 
Figure 1 EKG on Presentation - ST II, III, AVF- Inferior Leads – STEMI 
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 Figure 2 Right Sided EKG, ST elevation in Leads V3, V4, V5, V6 and II, III, AVF with 
reciprocal changes in AVL 
 
Figure 3 Cardiac Catheterization- normal, no occlusion 
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 Figure 4 Cardiac Catheterization- normal, no occlusion 
 
 
 
Figure 5 Pulmonary angiography, No Pulmonary Embolism visualized 
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 Figure 6 EKG 3, pre-discharge 
A diagnosis of Kounis syndrome was made and no percutaneous coronary intervention was 
performed. The patient was started on norepinephrine, decadron and anti-histamines then 
transferred to the ICU for further management and observation.  During her stay in the ICU, she 
was weaned off epinephrine infusion and continued on scheduled decadron. The patient showed 
signs of improvement and was eventually extubated on the second day of hospital stay.  An 
echocardiogram was performed which showed an ejection fraction of 60-65% with no wall 
motion abnormality and normal right ventricular size and function.  The patient remained stable 
and was transferred out to the floor and observed for a day, after which she was discharged 
home. 
Discussion 
Myocardial infarction is often associated with occlusive coronary artery disease (CAD) but 
myocardial infarctions in presence of non-obstructed coronary arteries have been reported to be 
as high as 6%.9 Coronary artery spasm is attributed to be a major cause for the acute coronary 
syndrome (ACS) associated with non-obstructed coronary arteries.9 In 1991, Dr. Nicholas 
Kounis defined Kounis syndrome [KS] as the occurrence of acute coronary syndrome in the 
presence of an allergic reaction.10 KS has three types: (i) Vasospastic allergic angina-ACS in 
patients with no underlying CAD, (ii) Allergic myocardial infarction-ASC in patients with 
underlying CAD and (iii) Stent thrombosis with occluding thrombus infiltrated by eosinophils-
ACS in patients with established coronary thrombus and stenting. In 2016 the definition of KS 
was revised to: the concurrence of acute coronary syndromes including coronary spasm, acute 
myocardial infarction, and stent thrombosis, with conditions associated with mast-cell and 
platelet activation and involving interrelated and interacting inflammatory cells, such as 
macrophages and T-lymphocytes, in the setting of allergic or hypersensitivity and anaphylactic 
or anaphylactoid insults.5  
Anaphylaxis is referred to as an immediate allergic reaction and or hypersensitivity type reaction. 
It clinically presents with hemodynamic instability and respiratory compromise; these entail 
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hypotension, tachycardia, bronchospasm, rhinorrhea, conjunctivitis, vasogenic edema, and 
pruritus.4,6,7 Although the exact mechanism is yet to be defined, general consensus encompasses 
release of vasoactive mediators that include namely histamine, serotonin, kinins and 
prostaglandins.4 Gueant-Rodriguez et al discussed potential pathogenic pathway by which 
iodinated contrast mediums cause immediate allergic reactions and delayed reactions.6 
Gadolinium-based contrast mediums (GCMs) are used for magnetic resonance investigation. The 
incidence of hypersensitivity reaction to GCM has been reported to vary between 0.7% to 2.4% 
while severe anaphylactic reaction occurs 0.004 to 0.01% of patients.11,12 There are various types 
of GCMs that are commonly utilized during magnetic resonance studies. For our patient 
gadobenate dimeglumine was being used for an MRI of the brain; it is a linear agent which is 
approved by FDA for central nervous system MRIs.13 The most common side effects listed by 
FDA are nephrogenic systemic fibrosis along with acute kidney injury and hypersensitivity. 
Cardiac arrhythmia is also listed as a side effect due to QTc prolongation but is not considered to 
be a major side effect.13 A post-marketing surveillance study demonstrated that acute adverse 
reaction rate for gadobenate dimeglumine ranged from 0.024% to 15%.14 The potential 
mechanism by which gadolinium causes hypersensitivity is not completely understood, but 
sensitization to gadolinium due to previous exposure is considered to be the most probable 
cause.7,12,15,16  
As per reviewed literature, our patient had an increased risk of gadolinium induced 
hypersensitivity. Studies have reported that gadolinium induced hypersensitivity is more 
common in women.7,17 Gadolinium is primarily excreted through the kidney15 and patients with 
elevated creatinine have a preponderance to hypersensitivity reactions. Our patient had a history 
of renal cell carcinoma, with an elevated creatinine of 1.4 and GFR of 44. Lastly, our patient had 
a remote history of an MRI with GCMs which probably would have worked as the sensitizing 
exposure. A case report by Singer et al similarly reported previous MRIs and exposure to 
gadolinium.15  
The mechanism by which ACS occurs in concurrence with allergic reaction was explained by 
Dr. Kounis.5 An allergic reaction is initiated when an allergen binds to the receptor bound IgE on 
mast cells or basophils and degranulation of inflammatory mediators occurs. These mediators are 
namely: histamine, chemokines, protease chymase, tryptase, cathepsin-D, proteoglycans, 
cytokines, peptides, growth factors, leukotrienes, thromboxane, platelet aggregating factor, 
prostacyclin and tumor necrosis factors. 
The management of KS is challenging because of the coexistence of two conditions that have 
high fatalities. The treatment must be directed towards restoring circulation to the myocardium 
and abating the anaphylaxis. Corticosteroids have an integral part in countering the effects of 
anaphylaxis and despite their controversial use in ACS patients, they are deemed to be 
appropriate treatment for KS. Another group of medications that are considered to be efficacious 
are antihistamines; the use of both H1 and H2 antagonists such as diphenhydramine (1 to 
2mg/kg) and ranitidine (1mg/kg) are advised, but the provider should keep in mind that 
concomitant use of these agents at a high rate causes hypotension leading to compromise of the 
coronary circulation, hence they should be infused slowly. Lastly, epinephrine can be used as it 
alleviates the life-threatening symptoms of anaphylaxis. Its use in KS is questionable as it has the 
potential to aggravate coronary vasospasm thereby potentiating the ischemia if administered 
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intravenously. Hence, intramuscular dose of 0.2 to 0.5mg should be given every 5 to 15 
minutes.18 
Treatment of ACS should be provided in accordance to the American College of Cardiology 
Foundation guidelines. The preferred mode for reperfusion of the myocardium is percutaneous 
coronary intervention. Medical management entails use of aspirin and an additive antiplatelet 
such as clopidogrel, prasugrel or any P2Y12 inhibitors only if there is no contraindication. 
Symptomatic relief and resolution of vasospasm can be achieved by intravenous nitroglycerin 
and/ or calcium channel blockers.18,19  
Conclusion 
Gadolinium-based contrast medium is generally a benign agent but in very rare cases it can lead 
to life threating conditions and physicians should be aware of the detrimental side effects of this 
contrast medium and also should be aware of Kounis syndrome as a potential serious 
complication of the GCM. 
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